February 19, 2018
FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults

February 04, 2016
Vertical / Trigen Holdings, LLC and Osmotica Holdings Corp Successfully Complete Combination

December 04, 2015
Vertical / Trigen Holdings, LLC and Osmotica Holdings Corp Limited to Combine, Creating World-Class, Fully-Integrated Specialty Pharmaceuticals Company

September 28, 2015
Osmotica Announces FDA Acceptance of Filing for Ontinua ER for Alleviation of Spasticity Resulting from Multiple Sclerosis and Strong Advancement in the Clinical Program for Osmolex ER

September 16, 2015
MONISTAT® and Vertical Pharmaceuticals Team Up to Help Healthcare Professionals Treat Yeast Infections

July 22, 2015
Osmotica Announces Its Second Late Stage NDA Asset, OS-320 ("Osmolex ER"), Has Been Awarded Orphan Drug Status by the United States Food and Drug Administration

July 08, 2015
Advancements in Osmotica's CNS Pipeline for Spasticity in MS Patients and LID in Parkinson's Patients

March 24, 2014
Vertical Pharmaceuticals, LLC Acquires Portfolio of Branded Women's Health Products from Upsher-Smith Laboratories, Inc.

December 16, 2013
Avista Capital Partners Announces a Majority Investment in Vertical Pharmaceuticals and Trigen Laboratories

September 27, 2013
Osmotica Announces the Commercial Launch of Its KHEDEZLA™ (desvenlafaxine) Extended-release Tablets, 50 mg and 100 mg